Prevention of Multidrug-Resistant Tuberculosis among Contacts (Literature Review)
https://doi.org/10.58838/2075-1230-2026-104-3-98-106
Abstract
This review summarizes the results of research on preventive treatment for multidrug-resistant tuberculosis (MDR-TB) contacts. A systematic literature search was conducted in the Google Scholar, PubMed and eLibrary databases to identify publications on the epidemiology and preventive treatment of MDR-TB contacts. The search covered the period from 2018 to 2025 using the following Medical Subject Headings (MeSH) keywords: “Tuberculosis, Multidrug-Resistant” / “Epidemiology”, “Transmission”, and “Prevention & Control”. Following the selection process, 41 publications were included in this literature review
Results. The literature review demonstrated that the development and implementation of new, highly effective and safe antituberculosis drugs in preventive treatment regimens for MDR-TB contacts represents a promising approach to reducing the incidence of multidrug-resistant tuberculosis.
About the Authors
S. I. Kayukova
Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation; National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Svetlana I. Kayukova, Doctor of Medical Sciences, Professor, Department of Phthisiology, Institute of Clinical Medicine; Leading Researcher, Laboratory of Microbiology, Virology and Molecular Biological Research Methods
1 Ostrovityanova St., 117997 Moscow;
Tel. +7 (495) 434-14-22
A. A. Prikhodko
Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation; National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Alena A. Prikhodko, Postgraduate Student, Department of Phthisiology, Institute of Clinical Medicine; Junior Researcher, Department of Differential Diagnosis and Treatment of Tuberculosis and Co-infections, Phthisiologist
1 Ostrovityanova St., 117997 Moscow;
Tel. +7 (495) 434-14-22
A. S. Polyakova
Moscow Research and Clinical Center for Tuberculosis Control, Moscow Government Department of Health
Russian Federation
Russian Federation
Alexandra S. Polyakova, District Phthisiologist, Zelenograd AD Branch, Moscow
10 Stromynka St., 107014 Moscow;
Tel. + 7 (499) 268-28-10
E. D. Sokolova
Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Elizaveta D. Sokolova, Resident, Department of Phthisiology, Institute of Clinical Medicine
1 Ostrovityanova St., 117997 Moscow;
Tel. +7 (495) 434-14-22
T. I. Sharkova
Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Tatyana I. Sharkova, Associate Professor, Department of Phthisiology, Institute of Clinical Medicine
1 Ostrovityanova St., 117997 Moscow;
Tel. +7 (495) 434-14-22
N. G. Ershova
Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Natalya G. Ershova, Associate Professor, Department of Phthisiology, Institute of Clinical Medicine
1 Ostrovityanova St., 117997 Moscow;
Tel. +7 (495) 434-14-22
References
1. Aksenova V.A., Baronova O.D., Baryshnikova L.A., Kazakov A.V., Klevno N.I. Latent tuberculosis infection in children. Clinical guidelines. Moscow, RPODP Zdorovie cheloveka Publ., 2024. (In Russ.)
2. Аksenovа V.A., Klevno N.I., Kаvtаrаshvili S.M., Kаzаkov A.V., Pаkhlаvonovа A.D. The nidus of tuberculous infection as a risk factor of multiple drug resistant tuberculosis in children. Tuberculosis and Lung Diseases. 2018;96(1):11-17. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-1-11-17
3. Vasilyeva I.A., Sterlikov S.A., Testov V.V., Mikhailov A.Yu., Golubev N.A., Kucheryavaya D.A., Ponomarev S.B. Resources and activities of TB control institutions of the Russian Federation in 2023–2024. Moscow, NMRC PP&ID, Ministry of Health of the Russian Federation, 2025. (In Russ.)
4. Guryeva T.I., Nikishova E.I., Zolotaya O.A., Sveshnikova O.M., Perkhin D.V., Maryandyshev A.O. Preventive Treatment of Tuberculosis with Fluoroquinolones Including Moxifloxacin in Children Exposed to Multidrug-Resistant Tuberculosis. Tuberculosis and Lung Diseases. 2025;103(4):24-31. (In Russ.) https://doi.org/10.58838/2075-1230-2025-103-4-24-31
5. Zhandauletova Zh.T., Nikishova E.I., Maryandyshev A.O., Serikbaeva K.S., Adenov M.M., Ismailov Sh.Sh., Sapieva Zh.A., Trusov A.A., Musabekova G.A., Kasymbekova S.Zh., Rakisheva A.S. Safety of new tuberculosis treatment regimens and compliance with these regimens according to data from the Republic of Kazakhstan. Tuberculosis and Lung Diseases. 2023;101(1):17-26. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-1-17-26
6. Clinical guidelines. Tuberculosis in children, 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/507_3 (Accessed: December 15, 2025). (In Russ.)
7. Nikiforenko N.A., Lozovskaya M.E., Novik G.А., Derevyanko А.V., Kochmarev N.V. The role of risk factors in the development of tuberculosis in children exposed to rifampicin resistant tuberculosis. Tuberculosis and Lung Diseases. 2021;99(7):18-25. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-7-18-25
8. Sterlikov S.A., Kucheryavaya D.A. Main epidemiological TB indicators in the Russian Federation for 2023. Resources and activities of the healthcare institutions providing phthisiatric care, 2024. Available at: https://t.me/TBStat (Accessed: December 15, 2025) (In Russ.)
9. Sterlikov S.A. Epidemiology of tuberculosis in children and adolescents in 2024. Available at: https://t.me/TBStat (Accessed: December 15, 2025). (In Russ.)
10. Ahmed S., Lotia-Farrukh I., Khan P.Y., Adnan S., Sodho J.S., Bano S., Siddiqui M.R., Ghafoor A., Isani A.K., Salahuddin N., Khan U. High prevalence of multidrug-resistant TB among household contacts in a high burden setting // The international journal of tuberculosis and lung disease. – 2023. – Vol. 27, № 8. – P. 646-648. https://doi.org/10.5588/ijtld.23.0123
11. Akalu T.Y., Clements A.C.A., Gebreyohannes E.A., Gilmour B., Alene K.A. Prevalence of tuberculosis infection among contacts of drug-resistant tuberculosis patients: A systematic review and meta-analysis // The Journal of infection. – 2024. – Vol. 89, № 2. – Р. 106198. https://doi.org/10.1016/j.jinf.2024.106198
12. Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB. Available at: https://clinicaltrials.gov/study/NCT06568484?cond=Tuberculosis&term=breach&rank=1 [Accessed 27.09.2025].
13. Benhur J. S., Santosh K., Kunal D., Gajendra V. S., Hariharan, Rishabh G. A study of multidrug resistant tuberculosis among symptomatic household contacts of MDR-TB patients // Indian Journal of Tuberculosis. – 2021. – Vol. 68, № 1. – P. 25-31. https://doi.org/10.1016/j.ijtb.2020.09.030
14. Chatla C., Jaju J., Achanta S., Samyuktha R., Chakramahanti S., Purad C., Chepuri R., Nair S. A., Parmar M. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India – A systematic screening intervention // The Indian journal of tuberculosis. – 2018. – Vol. 65, № 3. – P. 218-224. https://doi.org/10.1016/j.ijtb.2018.02.004
15. Chihota V., Gombe M., Gupta A., et al. Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review // Drugs. – 2025. – Vol. 85, № 2. – P. 127-147. https://doi:10.1007/s40265-024-02131-3
16. Duong T., Brigden J., Simon Schaaf H., Garden F., Marais B.J., Anh Nguyen T., White I.R., Gibb D.M., Nhung N.V., Martinson N.A., Fairlie L., Martinez L., Layton C., Benedetti A., Marks G.B., Turner R.M., Seddon J.A., Hesseling A.C., Fox G.J. A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis // NEJM evidence. – Vol. 4, № 1. – Р. EVIDoa2400190. https://doi.org/10.1056/EVIDoa2400190
17. Fox G.J., Nguyen C.B., Nguyen T.A., et al. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial // BMJ Open. – 2020. – Vol.10, № 1. – Р. e033945. https://doi.org/10.1136/bmjopen-2019-033945
18. Fox G.J., Nhung N.V., Cam Binh N., Hoa N.B., Garden F.L., Benedetti A., Ngoc Yen P., Cuong N.K., MacLean E.L., Yapa H.M., Dowdy D.W., Lan N.H., Guevara-Rattray E., Duc Cuong P., Solomon O., Behr M.A., Marais B.J., Graham S.M., Menzies D., Thu Anh N., Marks G.B. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam // The New England journal of medicine. – 2024. – Vol. 391, № 24. – P. 2304-2314. https://doi.org/10.1056/NEJMoa2314325
19. Guidance on evidence generation on new regimens for tuberculosis preventive treatment. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.
20. Global tuberculosis report 2025. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO
21. Gupta A., Swindells S., Kim S., Hughes M.D., Naini L., Wu X., Dawson R., Mave V., Sanchez J., Mendoza A., Gonzales P., Kumarasamy N., Comins K., Conradie F., Shenje J., Fontain S.N., Garcia-Prats A., Asmelash A., Nedsuwan S., Mohapi L., Churchyard G. Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease // Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. – 2020. – Vol. 70, № 3. – P. 425-435. https://doi.org/10.1093/cid/ciz235
22. Gureva T., Turkova A., Yablokova E., Smirnova P., Sveshnikova O., Zolotaya O., Nikishova E., Heldal E., Hinderaker S., Seddon J. A., Mariandyshev A. Fluoroquinolone preventive therapy for children exposed to MDR-TB. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. – 2022. – Vol. 26, № 2. – P. 171-173. https://doi.org/10.5588/ijtld.21.0443
23. Hesseling A.C., Purchase S.E., Martinson N.A., Fairlie L., Schaaf H.S., Brigden J., Staples S., Gibb D.M., Garcia-Prats A., Conradie F., McGowan C., Layton C., Batist E., Demers A.M., Nyamathe S., Frigati L., Turner R., Duong T., Seddon J.A. Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis // The New England journal of medicine. – 2024. – Vol. 391, № 24. – P. 2315-2326. https://doi.org/10.1056/NEJMoa2314318
24. Hiruy N., Melese M., Habte D., Jerene D., Gashu Z., Alem G., Jemal I., Tessema B., Belayneh B., Suarez P.G. Comparison of the yield of tuberculosis among contacts of multidrug-resistant and drug-sensitive tuberculosis patients in Ethiopia using GeneXpert as a primary diagnostic test // International journal of infectious diseases: official publication of the International Society for Infectious Diseases. – 2018. – № 71. – P. 4-8. https://doi.org/10.1016/j.ijid.2018.03.011
25. Huang C.C., Becerra M.C., Calderon R., Contreras C., Galea J., Grandjean L., Lecca L., Yataco R., Zhang Z., Murray M. Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis // American journal of respiratory and critical care medicine. – 2020. – Vol. 202, № 8. – P. 1159-1168. https://doi:10.1164/rccm.201908-1576OC
26. Huynh J., Marais B.J. Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs // Therapeutic advances in infectious disease. – 2019. – № 6. – Р. 2049936119864737. https://doi.org/10.1177/2049936119864737
27. Kendall Michelle A. Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients: Study Protocol for the Phoenix Phase 3 Clinical Trial, 2025. Available at: https://ssrn.com/abstract=5292585 [Accessed 27.09.2025].
28. Kherabi Y., Tunesi S., Kay A., Guglielmetti L. Preventive Therapy for Contacts of Drug-Resistant Tuberculosis // Pathogens. – 2022. – № 11. – Р. 1189. https://doi.org/10.3390/pathogens11101189
29. Koch A., Mizrahi V. Mycobacterium tuberculosis // Trends Microbiol. – 2018. – Vol. 26, № 6. – P. 555-556. https://doi:10.1016/j.tim.2018.02.012
30. Liebenberg D., Gordhan B.G., Kana B.D. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management // Front Cell Infect Microbiol. – 2022. – № 12. – Р. 943545. https://doi:10.3389/fcimb.2022.943545
31. Migliori G.B., Tiberi S., Zumla A., Petersen E., Chakaya J.M., Wejse C., Muñoz Torrico M., Duarte R., Alffenaar J.W., Schaaf H.S., Marais B.J., Cirillo D.M., Alagna R., Rendon A., Pontali E., Piubello A., Figueroa J., Ferlazzo G., García-Basteiro A., Centis R. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network // International journal of infectious diseases: official publication of the International Society for Infectious Diseases. – 2020. – № 92S. – P. 15-25. https://doi.org/10.1016/j.ijid.2020.01.042
32. Nahid P., Mase S.R., Migliori G.B., Sotgiu G., Bothamley G.H., Brozek J.L., Cattamanchi A., Cegielski J.P., Chen L., Daley C.L., Dalton T.L., Duarte R., Fregonese F., Horsburgh C.R., Jr Ahmad Khan F., Kheir F., Lan Z., Lardizabal A., Lauzardo M., Mangan J.M., Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline // American journal of respiratory and critical care medicine. – 2019. – Vol. 200, № 10. – Р. e93-e142. https://doi.org/10.1164/rccm.201909-1874ST
33. Phyo A.M., Kumar A.M.V., Soe K.T., Kyaw K.W.Y., Thu A.S., Wai P.P., Aye S., Saw S., Win Maung H.M., Aung S.T. Contact Investigation of Multidrug-Resistant Tuberculosis Patients: A Mixed-Methods Study from Myanmar // Trop Med Infect Dis. – 2019. – Vol. 5, № 1. – Р. 3. https://doi.org/10.3390/tropicalmed5010003
34. Pradipta I.S., Forsman L.D., Bruchfeld J., Hak E., Alffenaar J.W. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis // J Infect. – 2018. – Vol. 77, № 6. – P. 469-478. https://doi:10.1016/j.jinf.2018.10.004
35. Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB). Available at: https://clinicaltrials.gov/ct2/show/NCT03568383 [Accessed 27.09.2025].
36. Rajeev K., RAS Kushwaha, Amita J., Zameerul H., Priyanka G., Sarika P. Tuberculosis Among Household Contacts of Multidrug-Resistant Tuberculosis Cases at a Tertiary Hospital in Lucknow, India // International Journal of Life-Sciences Scientific Research. – 2018. – Vol. 4, № 2. – P. 1707-1712. https://doi.org/10.21276/ijlssr.2018.4.2.16
37. Seddon J.A., Garcia-Prats A.J., Purchase S.E., Osman M., Demers A.M., Hoddinott G., Crook A.M., Owen-Powell E., Thomason M.J., Turkova A., Gibb D.M., Fairlie L., Martinson N., Schaaf H.S., Hesseling A.C. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP) // Trials. – Vol. 19, № 1. – P. 693. https://doi.org/10.1186/s13063-018-3070-0
38. Seddon J.A., Achar J., Malik A.A., et al. Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis // Lancet Infect Dis. – 2025. – Vol. 25, № 12. – Р. e692-e704. https://doi.org/10.1016/S1473-3099(25)00157-4
39. Seid G., Alemu A., Diriba G., Zerihun B., Abebaw Y., Moga S., Abdela S., Habtemariam S., Gumi B. Routine tuberculosis contact investigation yield and preventive treatment cascade in central Ethiopia // Heliyon. – 2024. – Vol. 10, № 10. – Р. e30942. https://doi.org/10.1016/j.heliyon.2024.e30942
40. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment, second edition. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO.
41. WHO consolidated guidelines on tuberculosis: Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022. PMID:35404556.
Review
For citations:
Kayukova S.I., Prikhodko A.A., Polyakova A.S., Sokolova E.D., Sharkova T.I., Ershova N.G. Prevention of Multidrug-Resistant Tuberculosis among Contacts (Literature Review). Tuberculosis and Lung Diseases. 2026;104(3):98-106. (In Russ.) https://doi.org/10.58838/2075-1230-2026-104-3-98-106
Views:
90
JATS XML
Email this article 